Company Overview and News

2
UBS warns staff over China travel after banker held in Beijing

9h channelnewsasia
HONG KONG: Swiss bank UBS Group AG. has asked its China wealth management staff to reconsider their travel plans to the country after authorities there asked one of its bankers to delay her departure from Beijing to meet with local officials, a person familiar with the matter said.
UBS ULSGF

2
UBS warns staff over China travel after banker held in Beijing: source

10h reuters
HONG KONG (Reuters) - Swiss bank UBS Group AG. (UBSG.S) has asked its China wealth management staff to reconsider their travel plans to the country after authorities there asked one of its bankers to delay her departure from Beijing to meet with local officials, a person familiar with the matter said.
UBS ULSGF

2
Wealth managers UBS and Julius Baer restrict travel to China after Singapore banker is detained

16h scmp
Two large global wealth managers have imposed restrictions on staff travel to China after a UBS Group AG employee was detained, underlining the challenges of capturing business in a country where fortunes are growing the fastest on the planet.
UBS ULSGF

2
Ex-HSBC banker guilty of money laundering at Paris drug trial

2018-10-19 theedgemarkets
PARIS (Oct 19): A former Geneva-based HSBC Holdings Plc banker was found guilty of money laundering, but cleared of related drug charges in a French trial of four brothers accused of operating a sophisticated ring to distribute drug money to wealthy clients.
SCGLF UBS SCGLY GLE ULSGF

12
London's Citigroup Tower said readied for US$1.6 bil sale

2018-10-16 theedgemarkets
(Oct 16): The owner of the Canary Wharf skyscraper that’s leased to Citigroup Inc is considering a sale of the building for more than 1.2 billion pounds (US$1.6 billion), as investors continue to line up for London’s trophy buildings, people with knowledge of the plan said.
BNPQY SVS GS GLSSP SCGLF UBS JBK C GSC TFG SCGLY BNPQF GSJ BNPZY CGBBW GLE GJS ULSGF

7
Crude Rises as Mystery of Missing Saudi Critic Strains Alliance

2018-10-15 rigzone
(Bloomberg) -- Oil advanced amid growing international outrage over the disappearance of a prominent Saudi Arabian critics that put relations between the U.S. and kingdom on a knife edge.
UBS OXY ULSGF

21
Weekly Commentary: Rude Awakening Coming

2018-10-14 seekingalpha
There's little satisfaction writing the CBB after a big down week in the markets. Motivation seems easier to come by after up weeks, perhaps my defiant streak kicking in. I find myself especially melancholy at the end of this week. There's a rude awakening coming - perhaps it's finally starting to unfold.
DGLD BATS 4162 CS FMCKI FMCKJ UGLD SCGLF UBS FMCCO FMCCP DSLV FMCCM VIIX FMCCN CSSLF VIIZ FMCCI FMCCJ SCGLY FMCCG FMCKO NYTAB FMCKP FMCKM FMCKN FMCKK FMCKL CSGKF NDAQ T FMCC 2007 ZIV USLV GLE TVIX FMCCS ULSGF FMCCT XIV

3
Door opens for UBS to take majority ownership of China JV

2018-10-12 reuters
HONG KONG (Reuters) - UBS Group AG (UBSG.S) may have moved a step closer towards becoming the first foreign bank to hold majority ownership of its Chinese investment banking operations, after two of its joint venture partners said they had put their stakes up for sale.
NMR 8604 N33 UBS NRSCF ULSGF

2
Unlikely winners from Hong Kong's market crash: retail investors

2018-10-12 theedgemarkets
Hong Kong retail investors who trade callable bull/bear contracts actually made a profit overall. Despite steady recent inflows into derivatives betting that the benchmark Hang Seng Index and Tencent Holdings Ltd would rebound, their holdings of bearish contracts were enough to weather the losses.
UBS 0700 ULSGF

2
Featured Stocks In October's Most Attractive/Most Dangerous Model Portfolios

2018-10-11 seekingalpha
12 new stocks make our Most Attractive list this month and 10 new stocks fall onto the Most Dangerous list this month.
UBS AAP ULSGF

2
French court refuses UBS#39; request to drop money laundering charge

2018-10-11 moneycontrol
A French court on Thursday threw out a request by Swiss bank UBS for the constitutional court to drop money laundering charges and limit proceedings to complicity in tax fraud, which carries lighter penalties.
UBS ULSGF

2
French court refuses UBS request to drop money laundering charge

2018-10-11 channelnewsasia
PARIS: A French court on Thursday (Oct 11) threw out a request by Swiss bank UBS to drop money laundering charges and limit trial proceedings to complicity in tax fraud, which carries lighter penalties.
UBS ULSGF

2
French court refuses UBS request to drop money laundering charge

2018-10-11 reuters
PARIS (Reuters) - A French court on Thursday threw out a request by Swiss bank UBS (UBSG.S) to drop money laundering charges and limit trial proceedings to complicity in tax fraud, which carries lighter penalties.
UBS ULSGF

8
US trial begins for London forex traders accused of rigging prices

2018-10-11 malaymail
NEW YORK, Oct 11 — A US prosecutor yesterday urged jurors in Manhattan federal court to find three former London-based currency traders guilty of scheming to rig prices, kicking off the latest trial to emerge from a US probe into the multitrillion-dollar foreign exchange market.
BCS BNPQY HSB 83SF 83SK UBS HSBC HBCYF 47MC C BNPQF HCS 0005 BNPZY CGBBW HSEA HSEB ULSGF

2
Hong Kong will add artificial islands to tackle housing crisis

2018-10-10 thestar.com.my
Bullish market: Cable cars move past residential flats at Lantau island in Hong Kong. An almost 15-year bull run in prices prompted UBS Group AG to name Hong Kong as the city most at risk of a housing bubble. — Reuters
UBS ULSGF

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...